Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 3/20 | 0.36 |
| ▸ | PGK2 | P07205 | 3/20 | 0.36 |
| ▸ | PPID | Q08752 | 2/20 | 0.35 |
| ▸ | PPIB | P23284 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | PPIG | Q13427 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915165 | 0.86 | ESR1 (0.38) | PGK1PGK2ENPP2CYP3A4LMNA | |
| SCHEMBL915243 | 0.86 | PGK1 (0.37) | PGK1PGK2ENPP2LMNANPC1 | |
| SCHEMBL8920661 | 0.85 | FDPS (0.38) | FDPSANPEPERAP2MAOACYP2C19 | |
| SCHEMBL917066 | 0.84 | HTT (0.37) | FDPSPGK1PGK2CYP3A4CYP1A2 | |
| SCHEMBL4633893 | 0.84 | TRPA1 (0.40) | PGK1PGK2ENPP2LMNAALDH1A1 | |
| SCHEMBL1760139 | 0.84 | PGK1 (0.36) | PGK1PGK2ENPP2CYP3A4CYP1A2 | |
| SCHEMBL1334895 | 0.84 | FPR2 (0.38) | PGK1PGK2ENPP2CYP3A4LMNA | |
| SCHEMBL1407856 | 0.84 | TRPA1 (0.42) | ANPEPCYP1A2TSHR | |
| SCHEMBL914038 | 0.83 | ANPEP (0.44) | ANPEPERAP2CYP1A2NPC1RAB9A | |
| SCHEMBL915768 | 0.82 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-8673882-B2 | Inhibitors of autotaxin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2014-03-18 | — | — | US | disclosed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2012100018-A1 | INHIBITORS OF AUTOTAXIN | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190650-A1 | Inhibitors of Autotaxin | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
| EP-1937652-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1932867-A1 | POLYESTER, PROCESS FOR PRODUCTION OF POLYESTER, AND POLYESTER MOLDED ARTICLE | Toyo Boseki Kabushiki Kasisha (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007135195-A1 | ECTONUCLEOTIDASE INHIBITORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-29 | — | — | WO | disclosed |
| EP-1842868-A1 | PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT | Toyo Boseki Kabushiki Kasisha (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1803780-A1 | Contrast dyes for inkjet lithographic printing plates | Agfa Graphics N.V. (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007071552-A2 | CONTRAST DYES FOR INKJET LITHOGRAPHIC PRINTING PLATES | AGFA GRAPHICS NV (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071550-A1 | INKJET INK FOR PREPARING LITHOGRAPHIC PRINTING PLATES AND METHOD FOR THEIR PREPARATION | AGFA GRAPHICS NV (BE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1801170-A1 | Inkjet ink for preparing lithographic printing plates and method for their preparation | Agfa Graphics N.V. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-5670493-A | ANGIOGENESIS INHIBITORS | ADIR ET COMPAGNIE (FR) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | FDPS 735/4885ANPEP 1536/4885ERAP2 2230/4885 |
| US-20120190650-A1 | Inhibitors of Autotaxin | ENPP2, PHPT1, PSPH | FDPS 1877/4885ANPEP 469/4885ERAP2 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.